Salivary CXCL13 in relation to scintigraphy in early detection of secondary Sjogren’s syndrome

Salivary CXCL13 in relation to scintigraphy in early detection of secondary Sjogren’s syndrome

Background Sjogren’s syndrome (SS) is a systemic autoimmune disease in which immune cells attack and destroy the exocrine glands. CXCL13 directs B-cell chemotaxis and is elevated in several autoimmune diseases. Objective To assess the role of salivary CXCL13 level as a screening tool in early detect...

Full description

Saved in:
Bibliographic Details
Published in:Egyptian Rheumatology and Rehabilitation Vol. 45; no. 4; pp. 153 - 158
Main Authors: Shalabi, Minah Allah H., Salwa, Musa G., al-Shishtawi, Hibah F., al-Hifnawi, Hanan E., Mikawi, Dalia M. E.
Format: Journal Article
Language:English
Published: Cairo, Egypt The Egyptian Society for Rheumatology and Rehabilitation 01-10-2018
Springer Berlin Heidelberg
Wolters Kluwer India Pvt. Ltd
Springer Nature B.V
SpringerOpen
Subjects:
CXCL13
Medicine & Public Health
Original Article
Rehabilitation
s syndrome
salivary
Scintigraphy
Sjogren
salivary
CXCL13
scintigraphy
s syndrome
Sjogren
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Sjogren’s syndrome (SS) is a systemic autoimmune disease in which immune cells attack and destroy the exocrine glands. CXCL13 directs B-cell chemotaxis and is elevated in several autoimmune diseases. Objective To assess the role of salivary CXCL13 level as a screening tool in early detection of secondary SS patients. Patients and methods Salivary CXCL13 levels using ELISA technique, Schirmer paper test and/or Lissamine green staining, and quantitative salivary scintigraphy excretion fraction were measured in 45 selected patients with primitive connective tissue disease (rheumatoid arthritis, systemic lupus erythematosus, or systemic sclerosis) and according to the American-European Consensus Group criteria, they were classified to three equal groups: group I were having SS; group II were having dryness manifestations but not completing the criteria for SS diagnosis (suspected SS); group III were having no SS, and 15 age-matched and sex-matched apparently healthy controls. Results A significantly higher salivary CXCL13 level on comparing SS patients to suspected, non-SS groups and controls (P<0.001). Salivary CXCL13 had a significant negative correlation with scintigraphy (P<0.01), a significant positive correlation with eye dryness signs (P<0.01), cutoff value of CXCL13 to diagnose SS was more than 40pg/ml and a cutoff value of salivary scintigraphy excretion fraction to diagnose SS was less than 33.1%. Conclusion Salivary CXCL13 is a sensitive biomarker for early detection of secondary SS.
ISSN:1110-161X
2090-3235
DOI:10.4103/err.err_39_18